Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Paul Schimmel
AddedMar 31, 2024
UpdatedMay 31, 2026
Paul Schimmel

Paul Schimmel

Board Member, Longwood Fund

Crunchbase

Paul Schimmel's Career

Longwood Fund
Longwood Fund

Boston, MA, US

Board Member· Board
aTyr Pharma
aTyr Pharma

San Diego, CA, US

Board Member· Board
Alnylam Pharmaceuticals aln
Alnylam Pharmaceuticals aln

Cambridge, MA, US

Co-Founder
Boragen
Boragen

Durham, NC, US

Co-Founder
Metabolon
Metabolon

Durham, NC, US

Co-Founder
Vividion Therapeutics
Vividion Therapeutics

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Paul Schimmel's Career

Longwood Fund
Longwood Fund
Investment FirmInvestment Firm202010Boston, MA, US
Board Member· Board

Leadership at Longwood Fund

Michelle DippMichelle DippCo-Founder
Christoph WestphalChristoph WestphalCo-Founder
RICHARD H. ALDRICHRICHARD H. ALDRICHCo-Founder
David DonabedianDavid DonabedianCEO
Chris WalshChris WalshBoard Member

Similar to Longwood Fund

Longitude CapitalLongitude CapitalMenlo Park, CA, USest. 2006Longitude CapitalMenlo Park, CA, US · est. 2006

Longitude Capital: A venture capital firm investing in biotech, medtech, and health solutions for improved life quality.

Investment Firm45
Longevity Vision FundLongevity Vision FundNew York City, NY, USest. 2019Longevity Vision FundNew York City, NY, US · est. 2019

LVF: A venture capital fund investing in disruptive healthcare technologies for longer, healthier lives.

Investment Firm15
The Longevity FundThe Longevity FundSan Francisco, CA, USest. 2011The Longevity FundSan Francisco, CA, US · est. 2011

Longevity Fund: Investing in human longevity through innovative investment solutions.

Investment Firm2
Longwood Capital PartnersLongwood Capital PartnersPortola Valley, CA, USLongwood Capital PartnersPortola Valley, CA, US

Longwood Capital Partners: Financial services in Portola Valley, CA

Investment Firm5
aTyr Pharma
aTyr Pharma
Public$402.5M892005San Diego, CA, US
Board Member· Board

Leadership at aTyr Pharma

Sanjay ShuklaSanjay ShuklaBoard Member
Jane GrossJane GrossBoard Member
Xiang-Lei YangXiang-Lei YangCo-Founder
Tim CoughlinTim CoughlinBoard Member
Sara ZaknoenSara ZaknoenBoard Member

Similar to aTyr Pharma

AlltrnaAlltrnaCambridge, MA, USTherapeuticsest. 2018AlltrnaCambridge, MA, US · est. 2018

Altrna: Pioneering tRNA therapeutics, deciphering tRNA biology to treat numerous diseases.

Series B · $159M82
Aytu BioPharmaAytu BioPharmaEnglewood, CO, USPharmaceuticals, Therapeuticsest. 2015Aytu BioPharmaEnglewood, CO, US · est. 2015

Aytu BioPharma: A global specialty healthcare firm focusing on urological disorders and male infertility.

Public · $36M164
Atara BiotherapeuticsAtara BiotherapeuticsSouth San Francisco, CA, UST-Cell Therapiesest. 2012Atara BiotherapeuticsSouth San Francisco, CA, US · est. 2012

Atara Biotherapeutics: A clinical-stage biotech firm dedicated to developing therapies for severe diseases.

Public · $499.8M334
AptinyxAptinyxEvanston, IL, USPharmaceuticalsest. 2015AptinyxEvanston, IL, US · est. 2015

Aptinyx Inc., a US-based bio-pharmaceutical company, specializes in developing novel treatments for brain and nervous system disorders.

Public · $273.9M12
Alnylam Pharmaceuticals aln
Alnylam Pharmaceuticals aln
Public$3.9B2k2002Cambridge, MA, US
Co-Founder

Leadership at Alnylam Pharmaceuticals aln

Colleen ReitanColleen ReitanBoard Member
Yvonne GreenstreetYvonne GreenstreetCEO
Amy SchulmanAmy SchulmanBoard Member
Phillip SharpPhillip SharpBoard Member
Bob LangerBob LangerCo-Founder
Dennis AusielloDennis AusielloBoard Member

Similar to Alnylam Pharmaceuticals aln

Ionis PharmaceuticalsIonis PharmaceuticalsCarlsbad, CA, USPharmaceuticalsest. 1989Ionis PharmaceuticalsCarlsbad, CA, US · est. 1989

Ionis Pharmaceuticals: A US-based biotech firm specializing in RNA-targeted drug discovery for unmet needs.

Public · $1.3B796
SirnaomicsSirnaomicsGaithersburg, MD, USTherapeuticsest. 2007SirnaomicsGaithersburg, MD, US · est. 2007

US-based Sirnaomics, Inc. is a biopharmaceutical firm specializing in ocular neovascularization therapeutics.

Public · $275M30
Silence TherapeuticsSilence TherapeuticsLondon, Greater London, GBRNA Therapeuticsest. 1994Silence TherapeuticsLondon, Greater London, GB · est. 1994

UK biotech co. discovering molecules with RNA tech to target genes in diseases with unmet needs.

Public · $248.7M120
Atalanta TherapeuticsAtalanta TherapeuticsBoston, MA, USRNA Therapiesest. 2018Atalanta TherapeuticsBoston, MA, US · est. 2018

Atalanta Therapeutics: A biotech pioneer in RNA interference-based treatments for neurodegenerative diseases.

Series A · $110M62
Boragen
Boragen
Angel$15.3M302015Durham, NC, US
Co-Founder

Leadership at Boragen

C. Tony LiuC. Tony LiuCo-Founder
Lucy ShapiroLucy ShapiroCo-Founder
Rob ReadnourRob ReadnourBoard Member
Gerald FinkGerald FinkCo-Founder
Kristina BurowKristina BurowBoard Member
Stephen BenkovicStephen BenkovicCo-Founder
Metabolon
Metabolon
Public$199.7M3022000Durham, NC, US
Co-Founder

Leadership at Metabolon

Christopher KerseyChristopher KerseyBoard Member
John RyalsJohn RyalsBoard Member
John OxaalJohn OxaalBoard Member
Tom CaskeyTom CaskeyBoard Member
Jeff ClarkJeff ClarkBoard Member
Jan LundbergJan LundbergBoard Member

Similar to Metabolon

Molecular BiometricsMolecular BiometricsNorwood, MA, USHealth Diagnosticsest. 2005Molecular BiometricsNorwood, MA, US · est. 2005

Molecular Biometrics develops non-invasive methods using metabolomic technologies for health evaluation.

Series B · $24.5M30
Panome BioPanome BioSt. Louis, MO, USBiomarker Discoveryest. 2022Panome BioSt. Louis, MO, US · est. 2022

Panome Bio: A next-gen biomarker discovery platform offering comprehensive metabolomics solutions, founded in 2022.

Series A · $6M13
Phenomix SciencesPhenomix SciencesRochester, MN, USBiotechest. 2017Phenomix SciencesRochester, MN, US · est. 2017

Phenomix Sciences: A biotech firm excelling in life science, metabolomics, and genomics.

Pre-Seed · $3.2M5
QuanterixQuanterixBillerica, MA, USBiomarker Analysisest. 2007QuanterixBillerica, MA, US · est. 2007

Quanterix: Advancing precision health science through digitized biomarker analysis in Lexington, US.

Public · $533.3M125
Vividion Therapeutics
Vividion Therapeutics
Acquired$371.5M02013San Diego, CA, US
Board Member· Board

Leadership at Vividion Therapeutics

John ClarkeJohn ClarkeBoard Member
Phil BaranPhil BaranCo-Founder
Tom WoiwodeTom WoiwodeBoard Member
Jin-Quan YuJin-Quan YuCo-Founder
Aleksandra RizoAleksandra RizoBoard Member
Benjamin CravattBenjamin CravattCo-Founder

Paul Schimmel's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Paul Schimmel

David P. BartelDavid P. BartelCo-Founder · Alnylam Pharmaceuticals alnJames BergerJames BergerCo-Founder · Caribou BiosciencesPhillip D. ZamorePhillip D. ZamoreBoard Member · Voyager TherapeuticsMarvin H. CaruthersMarvin H. CaruthersCo-Founder · Amgen VenturesSamir MitragotriSamir MitragotriFounder · i2o Therapeutics